Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis

This is a preview and has not been published.

Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis

Authors

  • Deborah Reis Estrella Postgraduate Program at the Federal University of Minas Gerais, Belo Horizonte/MG, Brazil
  • Eliane Mancuzo Department of Internal Medicine, Federal University of Minas Gerais. Belo Horizonte/MG, Brazil
  • Ricardo de Amorim Correa Department of Internal Medicine, Federal University of Minas Gerais. Belo Horizonte/MG, Brazil
  • Regina Tibana Department of Pulmonology, Federal University of Sao Paulo. Sao Paulo/SP, Brazil
  • Maria Raquel Soares Department of Pulmonology, Federal University of Sao Paulo. Sao Paulo/SP, Brazil
  • Carlos Alberto de Castro Pereira Department of Pulmonology, Federal University of Sao Paulo. Sao Paulo/SP, Brazil

Keywords:

family history, pulmonary fibrosis, Interstitial lung disease

Abstract

Background: Familial pulmonary fibrosis (FPF) is defined as the occurrence of any interstitial lung disease (ILD) in two or more first- or second-degree relatives. Although the most frequently reported phenotype is idiopathic pulmonary fibrosis (IPF), other forms of ILD have been identified, such as fibrotic hypersensitivity pneumonitis (fHP). This study aims to explore survival between patients with IPF and fHP substratified by presence or absence of self-reported familial pulmonary fibrosis.

METHODS: Family history was acquired systematically, and patients were stratified by IPF or fHP according to specific guidelines.  Clinical data on pulmonary function and imaging were collected during the first follow-up evaluation of patients. All cases were reviewed in multidisciplinary meetings. Other ILD diagnosis was excluded.  

RESULTS: A total of 198 participants were included: 88 with IPF and 110 with fHP. In the IPF group, 36 had familial forms (F-IPF), and in the fHP group, 30 had familial fHP (F-fHP).

The median follow-up time was 37 (3 - 1200) months. The variables age (hazard ratio [HR]: 1.03; 95% CI: 1.01 - 1.06; p = 0.01), FVC% (HR: 0.96; 95% CI: 0.94 - 0.98; p < 0.01), SpO2% (HR: 0.86; 95% CI: 0.76 - 0.97; p < 0.02), and family history of pulmonary fibrosis (HR: 1.79; 95% CI: 1.09 - 2.93; p = 0.02) were associated with mortality and were controlled before performing the survival curves. The median survival for the FPF group was 46 months compared to 75 months for the non-familial group (p = 0.009).

Conclusion: patients with familial presentations of IPF and fHP have significantly lower survival compared to patients with non-familial presentations of the same diseases. In clinical practice across many countries, genetic testing is not widely available, so family history should always be investigated.

References

References

1. Borie R, Kannengiesser C, Antoniou K, et al. European Respiratory Society statement on familial pulmonary fibrosis. Eur Respir J. 2023 Mar 16;61(3):2201383. doi: 10.1183/13993003.01383-2022.

2. Newton CA, Oldham JM, Ley B, et al. Telomere length and genetic variant associations with interstitial lung disease progression and survival. Eur Respir J. 2019 Apr 11;53(4):1801641. doi: 10.1183/13993003.01641-2018.

3. Cutting CC, Bowman WS, Dao N, et al. Family History of Pulmonary Fibrosis Predicts Worse Survival in Patients With Interstitial Lung Disease. Chest. 2021 May;159(5):1913-1921. doi: 10.1016/j.chest.2021.01.026.

4. Raghu G, Remy-Jardin M, Myers JL, et al.; American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society. Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2018 Sep 1;198(5):e44-e68. doi: 10.1164/rccm.201807-1255ST.

5. Raghu G, Remy-Jardin M, Ryerson CJ, et al. Diagnosis of Hypersensitivity Pneumonitis in Adults. An Official ATS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2020 Aug 1;202(3):e36-e69. doi: 10.1164/rccm.202005-2032ST. Erratum in: Am J Respir Crit Care Med. 2021 Jan 1;203(1):150-151. doi: 10.1164/rccm.v203erratum1. Erratum in: Am J Respir Crit Care Med. 2022 Aug 15;206(4):518. doi: 10.1164/rccm.v206erratum4.

6. Tibana RCC, Soares MR, Storrer KM, et al. Clinical diagnosis of patients subjected to surgical lung biopsy with a probable usual interstitial pneumonia pattern on high-resolution computed tomography. BMC Pulm Med. 2020 Nov 16;20(1):299. doi: 10.1186/s12890-020-01339-9.

Downloads

How to Cite

1.
Reis Estrella D, Mancuzo E, de Amorim Correa R, Tibana R, Soares MR, de Castro Pereira CA. Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2025 Dec. 7];42(4):16938. Available from: https://mail.mattioli1885journals.com/index.php/sarcoidosis/article/view/16938

Issue

Section

Letter to Editor

How to Cite

1.
Reis Estrella D, Mancuzo E, de Amorim Correa R, Tibana R, Soares MR, de Castro Pereira CA. Survival in familial idiopathic pulmonary fibrosis and fibrotic hypersensitivity pneumonitis. Sarcoidosis Vasc Diffuse Lung Dis [Internet]. [cited 2025 Dec. 7];42(4):16938. Available from: https://mail.mattioli1885journals.com/index.php/sarcoidosis/article/view/16938